Gastroenterology

Part 2: For Patients and Employers, 2023 Means a Changed Landscape

September 13th 2022

By Skylar Jeremias

The second part of this 4-part series looks at what patients and employers can expect when adalimumab biosimilars hit the market.

What Will Year 1 Look Like for Adalimumab Biosimilars?

September 11th 2022

By Skylar Jeremias

Podcast

As part of a larger series preparing for the US market entrance of adalimumab biosimilars in 2023, Steven Lucio, PharmD, BCPS, senior principal of pharmacy solutions at Vizient, makes predictions for how the rollout of these biosimilars may play out and offers advice to stakeholders for how to maintain a robust market.

Biosimilars Development Check-in: New Data for Celltrion, Samsung Bioepis Candidates

September 7th 2022

By Skylar Jeremias

Article

Celltrion Healthcare released positive data for an ustekinumab biosimilar, and Samsung Bioepis announced long-term safety and efficacy results for its adalimumab biosimilar.

Part 1: Biosimilars to Bring a Bumper Crop of Adalimumab Options

September 6th 2022

By Skylar Jeremias

Article

In the first article of a 4-part series, The Center for Biosimilars® offers specifics for each of the adalimumab biosimilar products coming in 2023 and explains why the experience in Europe may differ from what’s coming in the United States.

The Future of Anti-inflammatory Biosimilars

August 27th 2022

By Deana Ferreri, PhD

Article

A review article chronicled the emergence of anti-inflammatory biosimilars in the United States and European Union and made predictions for where the market is headed, especially as etanercept and adalimumab biosimilars gain more prominence.

Biosimilar Infliximab Deemed Safe, Effective in Pediatric Patients With IBD

August 22nd 2022

By Deana Ferreri, PhD

Article

Researchers found that an infliximab biosimilar was as safe and effective as the reference product (Remicade) in pediatric patients with inflammatory bowel disease. However, more studies on adalimumab biosimilars in pediatric patients are needed.

FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar

August 17th 2022

By Skylar Jeremias

Article

The FDA approval of Samsung Bioepis’ high-concentration, citrate-free formulation of Hadlima, a biosimilar referencing Humira (adalimumab), is the first high-concentration adalimumab biosimilar to be approved in the United States.

Q&A: How Will Biobetters Fit Into the Growing Biologics Market? Celltrion Executive Explains

August 6th 2022

By The Center for Biosimilars Staff

Article

In an interview with The Center for Biosimilars®, Hyoung Ki Kim, vice chairman and CEO of Celltrion Healthcare, breaks down the benefits of biobetters, how they differ from biosimilars, and how they could alter the future landscape of the biologics industry.

Vizient Market Outlook Report Predicts Trends for Adalimumab Biosimilars in 2023

August 2nd 2022

By Skylar Jeremias

Article

Vizient’s Pharmacy Market Outlook report offers predictions on how the emergence of adalimumab biosimilars in 2023 will affect the biosimilar industry and what actions should be taken in advance to ensure biosimilar adoption.

Real-World Study Produces Positive Data on CT-P13 in North American Patients With IBD

July 16th 2022

By Deana Ferreri, PhD

Article

A real-world study on Pfizer and Celltrion Healthcare’s infliximab biosimilar (infliximab-dyyb, Inflectra; CT-P13) demonstrated positive clinical and patient-reported outcomes in patients with inflammatory bowel disease (IBD) in the United States and Canada.